The chief medical officer of Passage Bio discussed research needs in FTD.
Mark Forman, MD, PhD
Advertisement
Articles by Mark Forman, MD, PhD
The chief medical officer of Passage Bio discussed the phase 1/2 upliFT-D study of PBFT02.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Naji Gehchan, MD, MBA, on Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis
2
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
3
Quarter Century Update: Thoughts on Reducing Costs of Goods
4
Quarter Century Update: Future Predictions for the Field
5
